• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Sunday, August 31, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News

Drugs from nature: Big effects of multiple compounds in small amounts

Bioengineer by Bioengineer
December 13, 2016
in Science News
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

FRANKFURT. Nature often produces a whole weaponry of active ingredients to ensure it is well prepared for any scenario that might occur. Pharmacists and medical experts have meanwhile learnt from this, since pathogens develop resistance more easily to single active drugs than to a combination therapy. The research group led by Professor Helge Bode has now discovered a whole class of new peptides with which bacteria are able to kill insect larvae.

The peptides, known as rhabdopeptide/xenortide peptides (RXPs), are produced exclusively by the bacterial genera Photorhabdus and Xenorhabdus. They live in symbiosis with nematodes, together with which they infect and kill insect larvae. Since many RXPs are toxic for eukaryotic cells (including insect cells) and are produced by many different strains of Xenorhabdus and Photorhabdus, they presumably play a very important role during infection.

One single strain of bacteria can produce up to 40 RXP derivates. As the research group, which is led by Professor Helge B. Bode, Merck Endowed Professor of Molecular Biotechnology at Goethe University Frankfurt, reported in the latest issue of Nature Chemistry, it was surprising to see that only a maximum of four enzymes is required for their production. Bode compares them with classic chemical catalysts for the formation of polymer chains. His group has successfully solved the mechanisms responsible for the production of the unusually high diversity of RXPs.

Why do the bacteria produce a whole library of RXPs instead of single compounds? The researchers explain that the bacteria cannot control into which insect larvae they are delivered by their nematode host. However, in order to survive they must be able to kill any insect quickly and efficiently and direct the mixture of substances at perhaps completely different target sites in the insect cells at the same time. "Imagine shooting with a shotgun", explains Bode, "even if you're a poor marksman, there's a good chance that the spray of bullets will ensure that at least one hits the target!"

Future work will focus on detecting the exact mode of action of the RXPs and identifying, by means of structure-activity analysis, particularly potent derivates, which can then be produced biotechnologically or chemically and perhaps used as insecticides.

###

A picture can be downloaded from: http://www.uni-frankfurt.de/64290802

Media Contact

Prof. Helge Bode
[email protected]
@goetheuni

http://www.uni-frankfurt.de

############

Story Source: Materials provided by Scienmag

Share12Tweet8Share2ShareShareShare2

Related Posts

GPER: Key Role in Metabolism and Disease Management

August 31, 2025

Scaling Evidence-Based Health Interventions in Africa: A Dialogue

August 31, 2025

Japanese Patients’ Preferences for Lipid-Lowering Injections

August 31, 2025

UBAP2L Deficiency Limits Colorectal Cancer Growth and Resistance

August 31, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Breakthrough in Computer Hardware Advances Solves Complex Optimization Challenges

    152 shares
    Share 61 Tweet 38
  • Molecules in Focus: Capturing the Timeless Dance of Particles

    142 shares
    Share 57 Tweet 36
  • New Drug Formulation Transforms Intravenous Treatments into Rapid Injections

    116 shares
    Share 46 Tweet 29
  • Do people and monkeys see colors the same way?

    112 shares
    Share 45 Tweet 28

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

GPER: Key Role in Metabolism and Disease Management

Scaling Evidence-Based Health Interventions in Africa: A Dialogue

Japanese Patients’ Preferences for Lipid-Lowering Injections

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.